Myopathy due to interaction of cyclosporine, atorvastatin and verapamil
DOI:
https://doi.org/10.32818/reccmi.a9n3a3Keywords:
cyclosporine, atorvastatin, verapamil, myopathyAbstract
It has been described a higher muscle toxicity when cyclosporine is used mixed with other drugs that interact with
enzymes from cytochrome P450 3A4 (CYP3A4), such as atorvastatin or verapamil. It is due to their shared metabolism
by these enzymes. A conscious prescription of drugs and keeping in mind that possible interactions may
occur, make it possible to avoid muscle destruction and acute renal failure risk. We introduce the case of a man
who developed myopathy due to treatment with cyclosporine, atorvastatin and verapamil.
A conscious prescription of drugs and keeping in mind that possible interactions may occur, make it possible to avoid muscle destruction and acute renal failure risk.
We introduce the case of a man who developed myopathy due to treatment with cyclosporine, atorvastatin and verapamil
Downloads
Metrics
References
Li S, Yu Y, Jin Z, Dai Y, Lin H, Jiao Z, et al. Prediction of pharmacokinetic drugdrug
interactions causing atorvastatin-induced rhabdomyolysis using physiologically
based pharmacokinetic modeling. Biomed Amp Pharmacother.
; 119: 109416. doi: https://doi.org/10.1016/j.biopha.2019.109416 (último DOI: https://doi.org/10.1016/j.biopha.2019.109416
acceso oct. 2024).
Yang Y, Li P, Zhang Z, Wang Z, Liu L, Liu X. Prediction of cyclosporin-mediated
drug interaction using physiologically based pharmacokinetic model
characterizing interplay of drug transporters and enzymes. Int J Mol Sci.
; 21(19): 7023. doi: https://doi.org/10.3390/ijms21197023 (último acceso DOI: https://doi.org/10.3390/ijms21197023
oct. 2024).
Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic
interaction between cyclosporine A and atorvastatin in renal
transplant recipients. Am J Transplant. 2001; 1(4): 382-6. doi: https://doi.
org/10.1034/j.1600-6143.2001.10415.x (último acceso oct. 2024).
Compston A. Aids to the investigation of peripheral nerve injuries. Medical
Research Council: Nerve Injuries Research Committee. His Majesty's Stationery
Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the
examination of the peripheral nervous system. By Michael O'Brien for the
Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain.
; 133(10): 2838-44. doi: https://doi.org/10.1093/brain/awq270 (último DOI: https://doi.org/10.1093/brain/awq270
acceso oct. 2024).
Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem
Y, et al. Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No
Interactions with Tacrolimus. Am J Transplant. 2005; 5(9): 2236-43. https://
doi.org/10.1111/j.1600-6143.2005.01005.x (último acceso oct. 2024).
Sainz de Medrano Sainz JI, Brunet Serra M. Influencia de la farmacogenética
en la diversidad de respuesta a las estatinas asociada a las reacciones
adversas. Adv Lab Med. 2023; 4(4): 353-364. doi: https://doi.org/10.1515/
almed-2023-0064 (último acceso oct. 2024).
Franco D, Henao Y, Monsalve M, Gutiérrez F, Hincapie J, Amariles P. Interacciones
medicamentosas de agentes hipolipemiantes: Aproximación para
establecer y valorar su relevancia clínica. Revisión estructurada. Farm Hosp.
; 37(6): 539-557. https://doi.org/10.7399/FH.2013.37.6.1077 (último acceso
oct. 2024).
Frey FJ. Pharmacokinetic determinants of cyclosporine and prednisone in
renal transplant patients. Kidney Int. 1991; 39(5): 1034-50. doi: https://doi. DOI: https://doi.org/10.1038/ki.1991.131
org/10.1038/ki.1991.131 (último acceso oct. 2024).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Olga González-Angulo, Josefa Andrea Aguilar-García, María Inés Fernández-Canedo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
